Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity-Reference-Cited by-同舟云学术

Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity

Published:2023-12 Issue: Volume:253 Page:126874
ISSN:0141-8130
Container-title:International Journal of Biological Macromolecules
language:en
Short-container-title:International Journal of Biological Macromolecules

Author:

Wang Xueqing,Shi Lulu,Wang Yirong,Chen Jia,Yang Zelan,Liu Chenglong,Liu Xiaomei,Li Yang,Zhang Can,Sun Anhui,Yan Huan,Sun Hui

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Biochemistry,Structural Biology

Reference55 articles.

1. Synthetic homogeneous glycoforms of the SARS-CoV-2 spike receptor-binding domain reveals different binding profiles of monoclonal antibodies;Ye;Angew. Chem. Int. Ed. Eng.,2021

2. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials;Yang;Lancet Infect. Dis.,2021

3. Next-generation vaccine platforms for COVID-19;van Riel;Nat. Mater.,2020

4. A materials-science perspective on tackling COVID-19;Tang;Nat. Rev. Mater.,2020

5. COVID-19 vaccine frontrunners and their nanotechnology design;Chung;ACS Nano,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19;International Journal of Biological Macromolecules;2024-02